Expand VSTM Menu
VSTM MENU

VSTM Latest Press Releases

-- August 6, 2026 --

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates Business Wire 4:01 PM

-- July 28, 2026 --

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer Business Wire 4:01 PM

-- July 23, 2026 --

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire 7:30 AM

-- July 22, 2026 --

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer Business Wire 4:01 PM

-- July 2, 2026 --

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- June 23, 2026 --

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors Business Wire 4:01 PM

-- June 17, 2026 --

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer Business Wire 7:30 AM

-- June 16, 2026 --

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer Business Wire 4:01 PM

-- June 15, 2026 --

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program Business Wire 4:01 PM

-- June 3, 2026 --

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Business Wire 4:01 PM

-- May 27, 2026 --

Verastem Oncology to Present at Jefferies Healthcare Conference Business Wire 7:30 AM

-- May 26, 2026 --

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors Business Wire 7:30 AM

-- May 12, 2026 --

Verastem Oncology to Present at Upcoming Investor Conferences Business Wire 7:30 AM

-- May 8, 2026 --

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer Business Wire 7:30 AM

-- May 7, 2026 --

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates Business Wire 4:01 PM

-- April 30, 2026 --

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer Business Wire 7:30 AM

-- April 23, 2026 --

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 Business Wire 7:30 AM

-- April 10, 2026 --

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers Business Wire 7:00 AM

-- April 2, 2026 --

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM
Market Data Delayed 15 Minutes